Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 4
- 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K · DOI · Paper page
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W · doi:10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Self-citationFeng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
Self-citationGlucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 672
Kendler, D. L., Marin, F., Zerbini, C. A. F., Russo, L. A., Greenspan, S. L., Zikan, V., Bagur, A., Malouf-Sierra, J., Lakatos, P., Fahrleitner-Pammer, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32137-2 · Cited by 598
Self-citationAging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed · Cited by 735
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Self-citationSaag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Self-citationPathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Glucocorticoid-induced osteoporosis: an update
Compston, J. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 471
Vascular Calcification: An Update on Mechanisms and Challenges in Treatment
Wu, M., Rementer, C., & Giachelli, C. M. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9712-z · Cited by 434
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J. J., Komaba, H., Ando, R., Kakuta, T., Fujii, H., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12058 · Cited by 402
Bone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 359
Self-citationEbeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Glucocorticoid-induced osteoporosis
Briot, K., & Roux, C. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000014 · Cited by 300
Gut, inflammation and osteoporosis: Basic and clinical concepts
Tilg, H., Moschen, A. R., Kaser, A., Pines, A., & Dotan, I. (2008) · Gut · doi:10.1136/gut.2006.117382 · Cited by 292
Prevention and treatment of systemic glucocorticoid side effects
Moghadam‐Kia, S., & Werth, V. P. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.04322.x · Cited by 286
Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A., Takayanagi, R., Tanaka, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0586-6 · Cited by 281
Protein chemical synthesis by serine and threonine ligation
Zhang, Y., Xu, C., Lam, H. Y., Lee, C. L., & Li, X. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221012110 · Cited by 272
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives
Seibel, M. J., Cooper, M. S., & Zhou, H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70045-7 · Cited by 226
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
COPD, Bone Metabolism, and Osteoporosis
Lehouck, A., Boonen, S., Decramer, M., & Janssens, W. (2011) · Chest · doi:10.1378/chest.10-1427 · Cited by 211
Self-citationHumphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42646 · Cited by 197
Saag, K. G., Wagman, R. B., Geusens, P., Adachi, J. D., Messina, O. D., Emkey, R., Chapurlat, R., Wang, A., Pannacciulli, N., & Lems, W. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30075-5 · Cited by 209
Self-citationOverview of treatment approaches to osteoporosis
Langdahl, B. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 207
Osteoporosis – a current view of pharmacological prevention and treatment
Crockett, J., & Das (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31504 · Cited by 206
Treating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 203
Medication-induced osteoporosis: screening and treatment strategies
Panday, K., Gona, A., & Humphrey, M. B. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14546350 · Cited by 201
Circulating Osteogenic Precursor Cells in Type 2 Diabetes Mellitus
Manavalan, J. S., Cremers, S., Dempster, D. W., Zhou, H., Dworakowski, E., Kode, A., Kousteni, S., & Rubin, M. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1546 · Cited by 195
Management of glucocorticoid-induced osteoporosis
Compston, J. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.259 · Cited by 192
Sikjaer, T., Rejnmark, L., Rolighed, L., Heickendorff, L., Mosekilde, L., & the Hypoparathyroid Study Group (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.470 · Cited by 188
Management of severe osteoporosis
Miller, P. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1124856 · Cited by 185
Shanbhogue, V. V., Hansen, S., Frost, M., Jørgensen, N. R., Hermann, A. P., Henriksen, J. E., & Brixen, K. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2573 · Cited by 183
Glucocorticoid-induced osteoporosis: 2019 concise clinical review
Adami, G., & Saag, K. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04906-x · Cited by 183
Self-citationMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments
Lane, N. E. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00498-x · Cited by 171
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Osteoporosis in Rheumatic Diseases
Adami, G., Fassio, A., Rossini, M., Caimmi, C., Giollo, A., Orsolini, G., Viapiana, O., & Gatti, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235867 · Cited by 168
Glucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rizzoli, R., & Biver, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.188 · Cited by 165
Davis, S., Simpson, E., Hamilton, J., James, M. M.-S., Rawdin, A., Wong, R., Goka, E., Gittoes, N., & Selby, P. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 164
PINP as a biological response marker during teriparatide treatment for osteoporosis
Krege, J. H., Lane, N. E., Harris, J. M., & Miller, P. D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2646-0 · Cited by 162
Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review
Gebauer, J., Higham, C., Langer, T., Denzer, C., & Brabant, G. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00092 · Cited by 161
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Side effects of drugs for osteoporosis and metastatic bone disease
Skjødt, M. K., Frost, M., & Abrahamsen, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13759 · Cited by 171
Advances in Glucocorticoid-Induced Osteoporosis
den Uyl, D., Bultink, I. E. M., & Lems, W. F. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0173-y · Cited by 162
Nabipour, I., Sambrook, P. N., Blyth, F., Janu, M. R., Waite, L. M., Naganathan, V., Handelsman, D. J., Couteur, D. G. L., Cumming, R. G., & Seibel, M. J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.286 · Cited by 152
New understanding and treatments for osteoporosis
Mazziotti, G., Bilezikian, J. P., CANALIS, E. M., Cocchi, D., & Giustina, A. (2011) · Endocrine · doi:10.1007/s12020-011-9570-2 · Cited by 152
Using biochemical markers of bone turnover in clinical practice
Singer, F. R., & Eyre, D. W. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.739 · Cited by 153
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
Cosman, F., Lewiecki, E. M., Eastell, R., Ebeling, P. R., de Beur, S. M. J., Langdahl, B. L., Rhee, Y., Fuleihan, G. E., Kiel, D. P., Schousboe, J. T., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae119 · Cited by 184
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Cosman, F., Lane, N. E., Bolognese, M. A., Zanchetta, J., García-Hernández, P. A., Sees, K. H., Matriano, J. A., Gaumer, K., & Daddona, P. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0358 · Cited by 149
Parathyroid hormone analogues in the treatment of osteoporosis
KRAENZLIN, M. E., & Meier, C. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.108 · Cited by 151
Regulation of Wnt/β-catenin signaling within and from osteocytes
Burgers, T., & Williams, B. O. (2013) · Bone · doi:10.1016/j.bone.2013.02.022 · Cited by 176
Safety of osteoanabolic therapy: A decade of experience
Capriani, C., Irani, D., & Bilezikian, J. P. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1800 · Cited by 142
Saag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales‐Torres, J., Emkey, R. D., Butler, P. W., Yin, X., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40874 · Cited by 139
Self-citationHadji, P., Zanchetta, J., Russo, L. A. T., Recknor, C. P., Saag, K. G., McKiernan, F. E., Silverman, S. L., Alam, J., Burge, R. T., Krege, J. H., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1856-y · Cited by 144
Self-citationSato, A. Y., Cregor, M. D., Delgado‐Calle, J., Condon, K. W., Allen, M. R., Peacock, M., Plotkin, L. I., & Bellido, T. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2869 · Cited by 136
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
Migliorini, F., Colarossi, G., Eschweiler, J., Oliva, F., Driessen, A., & Maffulli, N. (2022) · British Medical Bulletin · doi:10.1093/bmb/ldac017 · Cited by 130
Briot, K., Cortet, B., Roux, C., Fardet, L., Abitbol, V., Bacchetta, J., Buchon, D., Debiais, F., Guggenbuhl, P., Laroche, M., et al. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.10.001 · Cited by 131
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Comprehensive Care of the Lung Transplant Patient
Adegunsoye, A., Strek, M. E., Garrity, E. R., Guzy, R. D., & Bag, R. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.001 · Cited by 130
Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (Review)
Tian, L., & Yu, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3472 · Cited by 135
Langdahl, B. L., Marín, F., Shane, E. J., Dobnig, H., Zanchetta, J., Maricic, M. J., Krohn, K., See, K., & Warner, M. R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0917-y · Cited by 126
Self-citationOsteoporosis-associated Fracture and Diabetes
Kurra, S., Fink, D. A., & Siris, E. S. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.004 · Cited by 124
Teriparatide: A Review of its Use in Osteoporosis
Blick, S. K. A., Dhillon, S., & Keam, S. J. (2008) · Drugs · doi:10.2165/0003495-200868180-00012 · Cited by 126
Monoclonal gammopathy of undetermined significance: a consensus statement
Berenson, J. R., Anderson, K. C., Audell, R. A., Boccia, R. V., Coleman, M., Dimopoulos, M. A., Drake, M. T., Fonseca, R., Harousseau, J., Joshua, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08207.x · Cited by 123
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 159
Romosozumab and antiresorptive treatment: the importance of treatment sequence
Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06174-0 · Cited by 120
Bone Disease in CKD: A Focus on Osteoporosis Diagnosis and Management
Miller, P. D. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.018 · Cited by 119
Weinstein, R. S., Jilka, R. L., Almeida, M., Roberson, P. K., & Manolagas, S. C. (2010) · Endocrinology · doi:10.1210/en.2009-1488 · Cited by 116
Geusens, P., Marín, F., Kendler, D. L., Russo, L. A. T., Zerbini, C. A. F., Minisola, S., Body, J. J., Lespessailles, É., Greenspan, S. L., Bagur, A., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3384 · Cited by 116
Self-citationYao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 119
Secondary Causes of Osteoporosis
Hudec, S. M. D., & Camacho, P. M. (2012) · Endocrine Practice · doi:10.4158/ep12059.ra · Cited by 133
Glucocorticoid-induced Osteoporosis
Whittier, X., & Saag, K. G. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.005 · Cited by 117
Self-citationMazziotti, G., Formenti, A. M., Adler, R. A., Bilezikian, J. P., Grossman, A. B., Sbardella, E., Minisola, S., & Giustina, A. (2016) · Endocrine · doi:10.1007/s12020-016-1146-8 · Cited by 119
Díez‐Pérez, A., Marín, F., Eriksen, E. F., Kendler, D. L., Krege, J. H., & Delgado‐Rodríguez, M. (2018) · Bone · doi:10.1016/j.bone.2018.09.020 · Cited by 116
Self-citationSteroids in neurooncology: actions, indications, side-effects
Roth, P., Wick, W., & Weller, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833e5a5d · Cited by 123
Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients
Evenepoel, P. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.019 · Cited by 118
Langdahl, B. L., Silverman, S. L., Fujiwara, S., Saag, K. G., Napoli, N., Soen, S., Enomoto, H., Melby, T. E., Disch, D. P., Marín, F., et al. (2018) · Bone · doi:10.1016/j.bone.2018.07.013 · Cited by 110
Self-citationSatterwhite, J. H., Heathman, M. A., Miller, P. D., Marín, F., Glass, E. V., & Dobnig, H. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9424-6 · Cited by 111
Self-citationParathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy
Leder, B. Z. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0353-4 · Cited by 116
Diabetes and bone health: the relationship between diabetes and osteoporosis‐associated fractures
Kurra, S., & Siris, E. S. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1197 · Cited by 106
Effect of Teriparatide on Early Bone Loss After Kidney Transplantation
Cejka, D., Benesch, T., Krestan, C. R., Roschger, P., Klaushofer, K., Pietschmann, P., & Haas, M. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02327.x · Cited by 105
Laurent, M. R., Goemaere, S., Verroken, C., Bergmann, P., Body, J., Bruyère, O., Cavalier, E., Rozenberg, S., Lapauw, B., & Gielen, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.908727 · Cited by 124
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Rossi, C. M., & Comite, G. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmc073408 · Cited by 102
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.